JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab.
Rey
J
J
Département d'Onco-Hématologie, Institut J. Paoli-Calmettes, Marseille, France. reyj@marseille.fnlcc.fr
Belmecheri
N
N
Bouayed
N
N
Ivanov
V
V
Coso
D
D
Gastaut
J A
JA
Bouabdallah
R
R
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003704:Dementia / Q000150:complications / Q000235:genetics / Q000821:virology; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007577:JC Virus / Q000187:drug effects / Q000502:physiology*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000150:complications* / Q000821:virology; D020522:Lymphoma, Mantle-Cell / Q000150:complications* / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone